Additionally, RIPK3 inhibitors have been shown to reduce the necrosis of CD4 + T cells, differentiation of Th17 cells, and expression of pro-inflammatory cytokines [107], all of which are important colitis-inducing factors. Here, RIPK3 is linked to colitis.